Selecting a dependable supplier for growth hormone-releasing hormone (GHRH) analogs requires rigorous analytical validation, transparent lot traceability, and strict quality control standards. This guide details where to buy CJC-1295 for preclinical research, what quality benchmarks to demand from vendors, and how the compound functions in laboratory settings.
Selecting a dependable supplier for growth hormone-releasing hormone (GHRH) analogs requires rigorous analytical validation, transparent lot traceability, and strict quality control standards. This guide details where to buy CJC-1295 for preclinical research, what quality benchmarks to demand from vendors, and how the compound functions in laboratory settings.
To buy CJC-1295 for laboratory research, investigators should source directly from domestic chemical suppliers that provide lot-specific third-party certificates of analysis (COA), RP-HPLC purity verification exceeding 98%, mass spectrometry identity confirmation, and low endotoxin thresholds. PX1 Research provides USA-manufactured CJC-1295 synthesized in ISO 17025 accredited facilities with complete analytical documentation for accurate in vitro and preclinical experimentation.
When procuring experimental peptides online, relying on unverified international resellers or vendors without comprehensive laboratory testing risks sample degradation, sequence errors, and batch-to-batch inconsistency. Principal investigators and lab managers evaluating all research peptides must prioritize manufacturers that uphold Good Manufacturing Practice (GMP) standards for research-grade chemical synthesis. Purchasing from established domestic entities like PX1 Research ensures uninterrupted supply chain integrity, rapid fulfillment, and verified compound identity required for publishable research.
CJC-1295 is a synthetic 29-amino-acid peptide derivative of growth hormone-releasing hormone (GHRH), specifically optimized to extend the biological half-life of the native peptide. Native GHRH (1-44) and its short-acting truncated derivative GRF (1-29) suffer from rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) in physiological environments, resulting in a metabolic half-life of less than ten minutes. CJC-1295 incorporates specific amino acid substitutions—D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27—to enhance enzymatic stability while retaining high affinity for the GHRH receptor.
In preclinical models, CJC-1295 acts as a selective GHRH receptor agonist. Upon binding to the GHRH receptor on somatotroph cells in the anterior pituitary, it activates the adenylate cyclase-cAMP-protein kinase A pathway. This signaling cascade stimulates the transcription and pulsatile secretion of endogenous growth hormone (GH). In turn, circulating GH acts on hepatic tissue to stimulate the synthesis of insulin-like growth factor 1 (IGF-1). Researchers interested in GHRH axis kinetics can explore the fundamental biochemistry in our detailed GHRH analog chemistry guide.
The primary objective of utilizing CJC-1295 in experimental designs is to maintain elevated serum GH and downstream IGF-1 levels over extended observation windows. Because IGF-1 serves as a master mediator of cellular proliferation, protein synthesis, and tissue regeneration, CJC-1295 provides a robust model for evaluating GHRH-mediated tissue repair pathways without requiring frequent continuous microinfusion.
When researching where to buy CJC-1295, investigators frequently encounter two distinct chemical variants: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also known as Modified GRF 1-29). Understanding the structural and pharmacokinetic differences between these two compounds is critical for designing appropriate experimental protocols.
The DAC modification consists of a reactive maleimido derivative attached via a lysine linker at the C-terminus of the 29-amino-acid peptide chain. In vivo, this maleimide group forms a covalent bond with free cysteine-34 residues on circulating serum albumin. By conjugating with endogenous albumin, the peptide escapes renal clearance and enzymatic degradation, extending its biological half-life from hours to over six days in rodent models. This sustained presence leads to prolonged elevated basal GH and IGF-1 elevation.
Conversely, CJC-1295 No DAC lacks this albumin-binding motif. It retains the four stabilizing amino acid substitutions, granting it a half-life of approximately 30 minutes in laboratory settings—significantly longer than native GHRH, but far shorter than the DAC-bound variant. Researchers seeking to replicate acute, pulsatile GHRH signaling typically utilize the non-DAC variant, whereas those investigating constant GHRH stimulation utilize CJC-1295 DAC. For a deeper comparative analysis of these dynamics, refer to our CJC-1295 research guide.
The scientific literature surrounding CJC-1295 focuses predominantly on its downstream influence on tissue regeneration, musculoskeletal preservation, and metabolic regulation in laboratory models. Preclinical studies suggest that sustained GHRH receptor activation accelerates cellular turnover and matrix deposition in damaged connective tissues, including tendons, ligaments, and skeletal muscle.
In animal models of soft tissue injury, administration of GHRH analogs has been observed to upregulate collagen type I and type III expression. Increased systemic IGF-1 concentrations driven by CJC-1295 promote satellite cell activation and myotube hypertrophy following experimental mechanical stress. Furthermore, preclinical studies indicate that GHRH axis activation promotes lipid oxidation and alters substrate utilization in metabolic models, presenting a valuable framework for investigating metabolic homeostasis.
In vitro data indicate that CJC-1295 exposure alters chondrocyte proliferation and extracellular matrix synthesis in articular cartilage explants. These findings highlight the utility of long-acting GHRH analogs in cellular cartilage repair assays and osteogenic differentiation models. Researchers conducting metabolic or musculoskeletal assays can access analytical-grade materials directly through our main research product portal.
In laboratory investigation of the growth hormone secretagogue axis, researchers frequently compare GHRH analogs with selective ghrelin receptor agonists (GHRPs). Selecting the appropriate compound depends entirely on whether the experiment requires receptor-specific targeting, synergistic dual-pathway stimulation, or physiological pulse preservation.
For instance, Sermorelin represents the native GRF (1-29) sequence without stabilizing modifications, exhibiting a rapid clearance rate and short receptor engagement window suitable for acute secretion assays. In contrast, CJC-1295 DAC provides continuous GHRH receptor activation due to covalent albumin binding. When investigators require selective growth hormone stimulation without triggering cortisol or prolactin release, combining GHRH analogs with a selective ghrelin receptor agonist such as Ipamorelin is widely documented in preclinical literature to elicit a synergistic secretion curve far exceeding the additive effects of either peptide alone.
Determining where to buy CJC-1295 requires establishing stringent verification criteria to safeguard analytical accuracy. Because synthetic peptides are prone to sequence truncated byproducts, incomplete deprotection, and TFA salt retention during solid-phase peptide synthesis (SPPS), relying on unverified vendors introduces significant experimental noise.
A qualified supplier must provide comprehensive analytical documentation for every manufacturing lot. The core verification standards include:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): HPLC testing confirms chemical purity by separating the target peptide from synthesis byproducts. Laboratories should require a minimum of 98% purity for reproducible quantitative assays.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Mass spectrometry verifies the exact molecular weight of the peptide, confirming sequence identity and ensuring the absence of structural isomer defects.
3. Endotoxin Testing (LAL Assay): Bacterial endotoxins (lipopolysaccharides) alter cell culture viability and induce non-specific inflammatory responses in preclinical models. High-grade research reagents must present verified low endotoxin levels (<0.01 EU/mg).
4. Lot Traceability and ISO Accreditation: Testing must be conducted by independent ISO 17025 accredited laboratories with verifiable lot numbers linked directly to the shipped product.
PX1 Research enforces these quality control measures on every batch, maintaining transparent COA access for principal investigators and institution procurement offices.
To maintain the chemical stability and biological activity of CJC-1295 in a laboratory setting, proper storage and handling protocols must be strictly maintained. Lyophilized CJC-1295 is stable at room temperature for brief periods during transport but should be stored long-term at -20°C or -80°C in a desiccated environment upon arrival.
When preparing the peptide for in vitro or preclinical assays, reconstitution should be performed using bacteriostatic water or sterile analytical-grade diluents under a laminar flow hood. Gentle swirling should be employed to dissolve the lyophilized cake; vigorous agitation or vortexing must be avoided to prevent mechanical shearing of the peptide chain.
Once reconstituted, aqueous CJC-1295 solutions should be aliquoted into single-use polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles, which degrade peptide integrity. Reconstituted solutions must be stored at 2°C to 8°C and used within an established experimental timeline. Laboratories planning high-throughput protocols can coordinate volume needs via our wholesale lab account services.
PX1 Research serves as a premier USA-based supplier of high-purity research peptides, dedicated exclusively to supporting academic institutions, biotechnology firms, and independent research laboratories. All CJC-1295 offered by PX1 Research is synthesized in state-of-the-art domestic facilities adhering to GMP-compliant processes.
By maintaining domestic operations in California and Arizona, PX1 Research eliminates international shipping delays and customs interference, offering same-day dispatch for orders placed Monday through Friday before cut-off times. Each vial undergoes rigorous multi-point analytical inspection prior to release, guaranteeing that your laboratory receives compounds meeting exact mass purity and chemical identity requirements.
When assessing where to buy CJC-1295 for upcoming research projects, PX1 Research provides the analytical transparency, lot-specific COAs, and reliable domestic fulfillment required for high-impact scientific inquiry.
Where can I buy CJC-1295 with third-party testing?
You can buy analytical-grade CJC-1295 directly from PX1 Research. Every lot undergoes independent ISO 17025 laboratory verification via RP-HPLC and mass spectrometry, with downloadable Certificates of Analysis (COA) detailing purity and identity.
What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a Drug Affinity Complex that covalently binds to circulating albumin in vivo, extending its half-life to several days in animal models. CJC-1295 No DAC (Mod GRF 1-29) lacks this complex, resulting in a half-life of roughly 30 minutes, ideal for short-duration secretagogue studies.
What purity level is required for CJC-1295 in research assays?
Preclinical and in vitro research typically requires a minimum chemical purity of 98% determined by RP-HPLC. Substandard purity risks experimental variance due to synthesis truncated sequences and TFA residues.
How should lyophilized CJC-1295 be stored upon delivery?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a dry, dark environment. Upon reconstitution with sterile diluent, solution aliquots should be kept refrigerated at 2°C to 8°C and used promptly to prevent hydrolytic degradation.
What is the primary GHRH receptor target of CJC-1295?
CJC-1295 targets and selectively binds to the GHRH receptor on pituitary somatotroph cells, activating the cAMP/PKA intracellular pathway to stimulate endogenous growth hormone synthesis and secretion.
Are PX1 Research compounds intended for human clinical use?
No. All products supplied by PX1 Research, including CJC-1295, are strictly intended for laboratory research use only by qualified investigators. They are not for human or veterinary diagnostic or therapeutic applications.
Why is endotoxin testing critical when purchasing research peptides?
Bacterial endotoxins (lipopolysaccharides) can trigger non-specific immune activation in cell culture and preclinical models, confounding experimental data. PX1 Research enforces strict low-endotoxin thresholds across all research lots.
Does PX1 Research ship CJC-1295 domestically within the United States?
Yes. PX1 Research manufactures and dispatches all research compounds from facilities located in California and Arizona, providing rapid domestic shipping and same-day fulfillment for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.